Last reviewed · How we verify
PORFIMER SODIUM
PORFIMER SODIUM is a drug. It is currently FDA-approved (first approved 1995).
At a glance
| Generic name | PORFIMER SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
Common side effects
- Photosensitivity reactions
- Photosensitivity reactions
- Mild constipation
- Erythema
- Swelling
- Pruritus
- Burning sensation
- Feeling hot
- Blisters
- Increased hair growth
- Skin discoloration
- Skin nodule
Serious adverse events
- Esophageal perforation
- Esophageal edema
- Atrial fibrillation
- Anemia
- Gastric ulcer
- Ileus
- Peritonitis
- Sepsis
- Cataracts
- Fluid imbalance
Key clinical trials
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (PHASE1)
- Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (PHASE2)
- Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (PHASE1)
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (PHASE2)
- Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (PHASE1, PHASE2)
- Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (PHASE1)
- Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium (PHASE2)
- Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PORFIMER SODIUM CI brief — competitive landscape report
- PORFIMER SODIUM updates RSS · CI watch RSS
Frequently asked questions about PORFIMER SODIUM
What is PORFIMER SODIUM?
PORFIMER SODIUM is a Small molecule drug.
When was PORFIMER SODIUM approved?
PORFIMER SODIUM was first approved on 1995.
What development phase is PORFIMER SODIUM in?
PORFIMER SODIUM is FDA-approved (marketed).
What are the side effects of PORFIMER SODIUM?
Common side effects of PORFIMER SODIUM include Photosensitivity reactions, Photosensitivity reactions, Mild constipation, Erythema, Swelling, Pruritus. Serious adverse events: Esophageal perforation, Esophageal edema, Atrial fibrillation, Anemia.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing